TheralaseTechnologies Inc, the Toronto research company involved with use of laser based technologies as cancer fighters to destroy cancer cells and eradicate pains, was recently voted the best presentation at the 28th edition of the International Conference of Laser Medicines, held in Florence, earlier in November, 2015. The conference is designed to assist researchers in moving laser-based products out of the laboratory and into commercial use with the understanding and acknowledgement that guidelines are critical, especially in the medical field.
The International Conference of Laser Medicines, brings experts from many disciplines together to advance the use of lasers in medicine, and Therelase’s research technology combines the use of its patented line of Osmium- based Photo Dynamic Compounds with incident light at specific wavelengths, in a process that has demonstrated the destruction, and cancer fighter capability of certain cancer cells in models in the laboratory.
The anti-cancer research, which is to be published in a leading international scientific academic publisher based in Bologna, Italy, was conducted in collaboration with the Chemistry Department of Acadia University, and the Medical Biophysics department of the University of Toronto, has shown that cancer cells can be targeted and destroyed without effect on surrounding tissue, and the company has submitted the cancer fighter technology to the ethics board of the Princess Margaret Hospital for approval, while also applying to the FDA and Health Canada for Investigation Testing Authorization or ITA. On gaining approval, the company expects to begin enrolling patients inflicted with Non-Muscle Invasive Bladder Cancer for clinical testing of the lead Photo Dynamic Compound (PDC), known as TLD-1433, and its TLC-3000 anti-cancer technology.
Research into the cell- death mechanism continues, but investigations show that the combination of the Photo Dynamic Compound and wavelength-specific light in the green, red and near IF spectrum, selectively activates the destruction of cells, with the release of Oxygen within the cell membrane.When the environment is favorable, the results are death of the cell and malignant tissue, which can be up to a few inches below the surface. The cancer fighter treatment has also demonstrated the potential to prevent recurrence of tumors, as there was no regrowth noticed in testing models.
Theralase has also entered into collaborative studies with the University of Ulm in Germany to obtain a better understanding of the mechanisms involved. The research at the medical facility in Ulm will be conducted in three phases, by Dr. Angelika Rueck. The German facility specializes in imaging and microscopy at the sub atomic level, using highly specialized medical imaging equipment and techniques, and it is hoped that a better understanding of the process will eventually lead to better efficacies of the cancer fighter process.
Company President, Roger Dumoulin-White, expresses the pleasure the company has experienced in working with a renowned scientist as Dr. Rueck, who has been instrumental in helping Theralase, so far, to appreciate why the technology works. Therelase’s stock continues trading on the Toronto Venture Exchange, and Over the Counter (OTC) under the symbols, TLT and TLTFF respectively.